Stock Performance and Market Context
On 11 Mar 2026, Lupin Ltd. surged to Rs.2375, marking its highest price level in the past year. This milestone comes after two consecutive days of gains, during which the stock delivered a cumulative return of 2.51%. The day’s performance was broadly in line with the Pharmaceuticals & Biotechnology sector, which also showed resilience despite broader market weakness.
In contrast, the Sensex experienced a notable decline, falling by 775.62 points or 0.95% to close at 77,463.29 after opening flat. The benchmark index has been under pressure for three consecutive weeks, losing 6.46% over this period. Additionally, the Sensex is trading below its 50-day moving average, which itself is positioned beneath the 200-day moving average, signalling a cautious market backdrop.
Despite this, Lupin Ltd. has demonstrated relative strength, outperforming the Sensex’s 4.63% one-year return with a 19.50% gain over the same period. The stock’s 52-week low stands at Rs.1774, highlighting the significant appreciation it has achieved in recent months.
Technical Indicators Confirm Uptrend
Lupin’s price is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment of moving averages is a classic indicator of sustained upward momentum. Weekly and monthly technical indicators further support this trend, with the MACD signalling bullish momentum on both timeframes. Bollinger Bands also suggest a mildly bullish stance on the weekly chart and a bullish outlook monthly.
While the weekly RSI shows a bearish signal, this is often interpreted as a temporary pullback within a broader uptrend. Other momentum indicators such as the KST and Dow Theory readings provide a mixed but generally positive technical picture, reinforcing the stock’s current strength.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Financial Strength and Growth Metrics
Lupin Ltd. maintains a conservative capital structure with an average debt-to-equity ratio of just 0.10 times, reflecting low leverage. This financial prudence supports the company’s ability to sustain growth and navigate market fluctuations.
The company’s net sales have grown at an annualised rate of 11.42%, while operating profit margins stand robustly at 33.60%. Recent quarterly results have been positive for three consecutive quarters, underscoring consistent operational performance.
Profit before tax excluding other income (PBT less OI) reached Rs.1,833.91 crores in the latest quarter, representing a strong growth rate of 43.6% compared to the previous four-quarter average. Net sales for the quarter hit a record Rs.7,167.52 crores, further highlighting Lupin’s expanding business scale.
Return on capital employed (ROCE) for the half-year period is notably high at 22.22%, while return on equity (ROE) stands at 22%, indicating efficient utilisation of shareholder funds. The company’s price-to-book value ratio is 5.5, suggesting an attractive valuation relative to its peers, especially given its growth profile.
Institutional Confidence and Market Standing
Institutional investors hold a significant 47.08% stake in Lupin Ltd., reflecting confidence from entities with extensive analytical resources. This level of institutional ownership often correlates with market stability and informed trading activity.
According to MarketsMojo’s comprehensive assessment, Lupin scores a Mojo Score of 78.0 and holds a Buy grade, recently adjusted from a Strong Buy on 16 Feb 2026. The company ranks among the top 1% of over 4,000 stocks analysed, positioned 10th within the Mid Cap segment and 32nd across the entire market. These rankings underscore Lupin’s quality and market stature.
Curious about Lupin Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Consistent Returns and Peer Comparison
Over the past three years, Lupin Ltd. has consistently outperformed the BSE500 index annually, demonstrating steady value creation. The stock’s 19.50% return over the last year is complemented by a 73.5% increase in profits, resulting in a low PEG ratio of 0.3. This indicates that the company’s earnings growth is not fully reflected in its current price, relative to its growth rate.
Compared to its sector peers, Lupin trades at a discount to average historical valuations, offering a favourable entry point for those analysing valuation metrics. The company’s strong fundamentals, combined with technical momentum, have contributed to its recent price appreciation and new 52-week high.
Summary of Technical and Fundamental Strengths
Lupin Ltd.’s recent rally to Rs.2375 is supported by a confluence of factors: robust quarterly earnings, strong return ratios, low leverage, and positive technical signals across multiple timeframes. The stock’s ability to outperform the broader market and sector indices during a period of overall market weakness highlights its resilience and underlying strength.
While the Sensex faces headwinds and trades below key moving averages, Lupin’s price action and financial metrics present a contrasting narrative of growth and stability within the Pharmaceuticals & Biotechnology sector.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
